Alnylam is in a severe, sustained downtrend that has wiped out more than half of shareholder value over the trailing year, with the 1-year price change at -52.34% and the current price of $219.72 sitting at just 7.3% above the 52-week low of $197.81 and a staggering 55.7% below the 52-week high of $495.55. Measured against the 52-week range, the stock is trading at approximately 7.3% of its full range — a positioning that screams capitulation rather than opportunity, though it also means the stock is deeply oversold relative to its own history. The year-to-date decline of -45.09% and a max drawdown of -58.17% confirm this is not a garden-variety pullback but a structural repricing of the equity, and the fact that the stock is closer to its lows than at any point in the past year means momentum traders have no trend to lean on while value-oriented buyers face the classic falling-knife risk.

Short-term momentum is decisively negative and accelerating to the downside, with the 1-month change at -17.83%, the 3-month change at -29.75%, and the 6-month change at -31.09% — each successive window showing deterioration rather than stabilization. The most recent session alone saw a -4.96% drop from $231.18 to $219.72, and the 1-month relative strength versus the S&P 500 is a dismal -18.42%, meaning Alnylam is underperforming a market that itself gained 0.59% over the same period. This is a textbook negative divergence: the broader market (SPY +15.01% over 1 year, +12.86% YTD) has been rising while Alnylam has been collapsing, and the -67.35% 1-year relative strength figure underscores just how violently capital has rotated out of this name. The late-July 2026 gap from ~$286 to ~$205 on what appears to be a major negative catalyst remains the defining technical event, and the stock has been unable to reclaim even half of that lost ground.

Key technical levels are starkly defined: support sits at the 52-week low of $197.81, just 10% below the current $219.72, while resistance is anchored at the 52-week high of $495.55 — a level so distant it is almost irrelevant for near-term trading. A breakdown below $197.81 would signal a fresh leg lower and likely trigger momentum-driven selling, while any reclaim of the $250-270 zone (the post-gap consolidation range) would be the first meaningful sign of stabilization. The beta of 0.30 is a critical and counterintuitive data point: despite the stock's brutal drawdown, its low beta means it is theoretically only 30% as volatile as the broader market, which suggests the decline is driven by company-specific (idiosyncratic) factors rather than macro risk appetite — a distinction that matters enormously for position sizing, since the risk here is fundamentally binary and catalyst-driven rather than systematic. The short ratio of 4.19 indicates moderate short interest, not a crowded short, meaning there is no obvious squeeze setup to fuel a sharp reversal.

Alnylam's revenue trajectory has been nothing short of explosive, with Q2 2026 revenue of $1.291 billion representing 66.86% year-over-year growth versus Q2 2025's $773.7 million, and the multi-quarter trend shows consistent sequential expansion from $594.2 million in Q1 2025 to $1.291 billion in Q2 2026 — a more than doubling in just five quarters. The product segment dominates at $1.172 billion, with GIVLAARI contributing $89.8 million and ONPATTRO $18.5 million, indicating that the growth is overwhelmingly driven by the flagship Amvuttra franchise rather than legacy assets. This is a company that has crossed the chasm from clinical-stage promise to commercial execution, and the 66.86% growth rate is exceptional for a company of this size, implying the investment case rests on whether this pace can be sustained against competitive entrants in the hATTR amyloidosis market.

Profitability has inflected dramatically, with Q2 2026 net income of $164.5 million and a net margin of 12.74%, a stunning reversal from the -$66.3 million loss in Q2 2025 and the -$111.6 million loss in Q3 2024. Gross margin stands at 76.9% in Q2 2026, though this is down from 81.9% in Q1 2026 and 84.2% in Q3 2025, suggesting some margin compression as the revenue mix shifts and cost of revenue rises — cost of revenue jumped to $298.3 million in Q2 2026 from $211.1 million in Q1 2026. Operating margin of 17.93% and EBITDA of $244.7 million confirm the company is now generating real operating leverage, but the declining gross margin trend bears watching as it could signal pricing pressure or less favorable product mix. For a commercial-stage biotech, these margins are healthy but not exceptional, and the key question is whether R&D spending — $413.1 million in Q2 2026, up from $364.9 million in Q1 2026 — will continue to suppress net margins as the pipeline advances.

The balance sheet is solid but carries meaningful leverage, with a debt-to-equity ratio of 1.62, a current ratio of 2.76, and cash of $1.445 billion at the end of Q2 2026. Free cash flow on a trailing twelve-month basis is $542.5 million, but quarterly FCF has been volatile — $40.6 million in Q2 2026, $48.7 million in Q1 2026, and $140.3 million in Q4 2025 — and the Q2 2026 operating cash flow of just $75.3 million against $34.7 million in capex shows the company is generating cash but not at a level that comfortably covers its $82.1 million quarterly interest expense. ROE of 39.76% and ROA of 12.34% are impressive on the surface, but the high ROE is partly a function of the leveraged capital structure (equity multiplier of 4.1x), and the cash flow to debt ratio of just 0.059 signals that debt servicing consumes a meaningful portion of operating cash. The company is not dependent on external financing for survival — it has $1.4 billion in cash and positive FCF — but the capital structure leaves limited room for error if revenue growth decelerates.